TELOHealthcare · Biotechnology

TELO Stock Forecast: Telomir Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$1.15

+2.68% on the day

The 1 Wall Street analysts covering Telomir Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +247.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$77.0M

Ticker Nerd rank

28 / 100

Median analyst target

$4.00

Analysts covering

Revenue$0.0

Operating income−$1.8M

Net income−$1.7M

Free cash flow−$1.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−1.7%

−3.4%

YTD

−13.5%

−30.3%

From 52W high

−40.4%

From 52W low

+25.1%

$0.92

$1.93

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

TELO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Telomir Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Value

Accruals

Revisions

Growth

Momentum

Issuance

Quality

Size (76): Smaller than most of the companies we track.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TELO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +247.8% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
17 Sept 2026	Maxim Group	Initiates	Buy	$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELO appears on the weeks it earns a place.

Performance

TELO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Telomir Pharmaceuticals, Inc. returned −30.3% against +16.2% for the S&P 500, dividends included.

TELO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TELO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Telomir Pharmaceuticals, Inc. (TELO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.4×
Price / sales: —
Price / book: 15.3×
EV / EBITDA: −6.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −213.1%
Return on assets: −122.8%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Telomir Pharmaceuticals, Inc. (TELO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Telomir Pharmaceuticals, Inc. has a market value of $77.0M and an enterprise value of $72.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$5.9M.
Free cash flow in the twelve months to 30 June 2026: −$4.9M.
Shares outstanding: 68.8M.
Trailing P/E: −3.4×; forward P/E: −4.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Telomir Pharmaceuticals, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

TELO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
TELOTelomir Pharmaceuticals, Inc.	$77.0M	28
CGTXCognition Therapeutics, Inc.	$85.1M	35
NRXSNeurAxis, Inc.	$83.8M	58
NMRANeumora Therapeutics, Inc.	$87.3M	30
CRDFCardiff Oncology, Inc.	$81.7M	46
ICCCImmuCell Corp.	$88.2M	93
MISTMilestone Pharmaceuticals, Inc.	$88.7M	16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Telomir Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TELO news & analysis

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

GlobeNewsWire · 6 Oct 2026positive

Telomir Pharmaceuticals announced an approximately $5.6 million PIPE financing through the issuance of common stock, with no accompanying warrants or convertible securities. The financing includes an additional $1.0 million investment from existing significant shareholder John Paul DeJoria.

Why it matters — The financing adds capital to Telomir and includes a further investment from an existing significant shareholder.

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

GlobeNewsWire · 17 Sept 2026positive

Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that its investigational candidate Telomir-Zn improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The findings were announced via a press release on September 17, 2026.

Why it matters — The publication expands Telomir-Zn's potential therapeutic scope beyond its stated focus on cancer, adding a peer-reviewed preclinical data point in AMD for watchers to consider.

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

GlobeNewsWire · 14 Sept 2026positive

Telomir Pharmaceuticals announced findings from research conducted with The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models. The in-vitro results were reported via a press release on September 14, 2026.

Why it matters — The new research suggests Telomir-Zn may have anticancer activity in a challenging cancer type, which could signal expanded therapeutic potential for TELO shareholders.

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

GlobeNewsWire · 10 Aug 2026positive

Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that its candidate Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The announcement highlights the research findings from the publication.

Why it matters — This provides scientific validation for Telomir-Zn's therapeutic potential in two cancer types, which is directly relevant to the company's pipeline for TELO watchers.

FAQ

Frequently asked questions about TELO stock

What is the TELO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Telomir Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TELO stock a buy right now?

Of the 1 analysts covering Telomir Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Telomir Pharmaceuticals, Inc. 28 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TELO?

As at 8 Oct 2026, Telomir Pharmaceuticals, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (76 of 100).

Will TELO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +247.8% from the last close, and Ticker Nerd's factor model ranks Telomir Pharmaceuticals, Inc. 28 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TELO stock forecast for 2030?

No analyst covering Telomir Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has TELO stock performed over the past year?

Telomir Pharmaceuticals, Inc. returned -30.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Telomir Pharmaceuticals, Inc. do?

What is the latest news on TELO?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company". Telomir Pharmaceuticals announced an approximately $5.6 million PIPE financing through the issuance of common stock, with no accompanying warrants or convertible securities. The financing includes an additional $1.0 million investment from existing significant shareholder John Paul DeJoria.

Company

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.

CEO Mr. Erez Aminov · 1 employees · United States · https://telomirpharma.com